Cargando…

A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities

Personalized cancer treatments using combinations of drugs with a synergistic effect is attractive but proves to be highly challenging. Here we present an approach to uncover the efficacy of drug combinations based on the analysis of mono-drug effects. For this we used dose-response data from pharma...

Descripción completa

Detalles Bibliográficos
Autores principales: Narayan, Ravi S., Molenaar, Piet, Teng, Jian, Cornelissen, Fleur M. G., Roelofs, Irene, Menezes, Renee, Dik, Rogier, Lagerweij, Tonny, Broersma, Yoran, Petersen, Naomi, Marin Soto, Jhon Alexander, Brands, Eelke, van Kuiken, Philip, Lecca, Maria C., Lenos, Kristiaan J., In ‘t Veld, Sjors G. J. G., van Wieringen, Wessel, Lang, Frederick F., Sulman, Erik, Verhaak, Roel, Baumert, Brigitta G., Stalpers, Lucas J. A., Vermeulen, Louis, Watts, Colin, Bailey, David, Slotman, Ben J., Versteeg, Rogier, Noske, David, Sminia, Peter, Tannous, Bakhos A., Wurdinger, Tom, Koster, Jan, Westerman, Bart A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287046/
https://www.ncbi.nlm.nih.gov/pubmed/32523045
http://dx.doi.org/10.1038/s41467-020-16735-2
_version_ 1783544983868932096
author Narayan, Ravi S.
Molenaar, Piet
Teng, Jian
Cornelissen, Fleur M. G.
Roelofs, Irene
Menezes, Renee
Dik, Rogier
Lagerweij, Tonny
Broersma, Yoran
Petersen, Naomi
Marin Soto, Jhon Alexander
Brands, Eelke
van Kuiken, Philip
Lecca, Maria C.
Lenos, Kristiaan J.
In ‘t Veld, Sjors G. J. G.
van Wieringen, Wessel
Lang, Frederick F.
Sulman, Erik
Verhaak, Roel
Baumert, Brigitta G.
Stalpers, Lucas J. A.
Vermeulen, Louis
Watts, Colin
Bailey, David
Slotman, Ben J.
Versteeg, Rogier
Noske, David
Sminia, Peter
Tannous, Bakhos A.
Wurdinger, Tom
Koster, Jan
Westerman, Bart A.
author_facet Narayan, Ravi S.
Molenaar, Piet
Teng, Jian
Cornelissen, Fleur M. G.
Roelofs, Irene
Menezes, Renee
Dik, Rogier
Lagerweij, Tonny
Broersma, Yoran
Petersen, Naomi
Marin Soto, Jhon Alexander
Brands, Eelke
van Kuiken, Philip
Lecca, Maria C.
Lenos, Kristiaan J.
In ‘t Veld, Sjors G. J. G.
van Wieringen, Wessel
Lang, Frederick F.
Sulman, Erik
Verhaak, Roel
Baumert, Brigitta G.
Stalpers, Lucas J. A.
Vermeulen, Louis
Watts, Colin
Bailey, David
Slotman, Ben J.
Versteeg, Rogier
Noske, David
Sminia, Peter
Tannous, Bakhos A.
Wurdinger, Tom
Koster, Jan
Westerman, Bart A.
author_sort Narayan, Ravi S.
collection PubMed
description Personalized cancer treatments using combinations of drugs with a synergistic effect is attractive but proves to be highly challenging. Here we present an approach to uncover the efficacy of drug combinations based on the analysis of mono-drug effects. For this we used dose-response data from pharmacogenomic encyclopedias and represent these as a drug atlas. The drug atlas represents the relations between drug effects and allows to identify independent processes for which the tumor might be particularly vulnerable when attacked by two drugs. Our approach enables the prediction of combination-therapy which can be linked to tumor-driving mutations. By using this strategy, we can uncover potential effective drug combinations on a pan-cancer scale. Predicted synergies are provided and have been validated in glioblastoma, breast cancer, melanoma and leukemia mouse-models, resulting in therapeutic synergy in 75% of the tested models. This indicates that we can accurately predict effective drug combinations with translational value.
format Online
Article
Text
id pubmed-7287046
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-72870462020-06-16 A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities Narayan, Ravi S. Molenaar, Piet Teng, Jian Cornelissen, Fleur M. G. Roelofs, Irene Menezes, Renee Dik, Rogier Lagerweij, Tonny Broersma, Yoran Petersen, Naomi Marin Soto, Jhon Alexander Brands, Eelke van Kuiken, Philip Lecca, Maria C. Lenos, Kristiaan J. In ‘t Veld, Sjors G. J. G. van Wieringen, Wessel Lang, Frederick F. Sulman, Erik Verhaak, Roel Baumert, Brigitta G. Stalpers, Lucas J. A. Vermeulen, Louis Watts, Colin Bailey, David Slotman, Ben J. Versteeg, Rogier Noske, David Sminia, Peter Tannous, Bakhos A. Wurdinger, Tom Koster, Jan Westerman, Bart A. Nat Commun Article Personalized cancer treatments using combinations of drugs with a synergistic effect is attractive but proves to be highly challenging. Here we present an approach to uncover the efficacy of drug combinations based on the analysis of mono-drug effects. For this we used dose-response data from pharmacogenomic encyclopedias and represent these as a drug atlas. The drug atlas represents the relations between drug effects and allows to identify independent processes for which the tumor might be particularly vulnerable when attacked by two drugs. Our approach enables the prediction of combination-therapy which can be linked to tumor-driving mutations. By using this strategy, we can uncover potential effective drug combinations on a pan-cancer scale. Predicted synergies are provided and have been validated in glioblastoma, breast cancer, melanoma and leukemia mouse-models, resulting in therapeutic synergy in 75% of the tested models. This indicates that we can accurately predict effective drug combinations with translational value. Nature Publishing Group UK 2020-06-10 /pmc/articles/PMC7287046/ /pubmed/32523045 http://dx.doi.org/10.1038/s41467-020-16735-2 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Narayan, Ravi S.
Molenaar, Piet
Teng, Jian
Cornelissen, Fleur M. G.
Roelofs, Irene
Menezes, Renee
Dik, Rogier
Lagerweij, Tonny
Broersma, Yoran
Petersen, Naomi
Marin Soto, Jhon Alexander
Brands, Eelke
van Kuiken, Philip
Lecca, Maria C.
Lenos, Kristiaan J.
In ‘t Veld, Sjors G. J. G.
van Wieringen, Wessel
Lang, Frederick F.
Sulman, Erik
Verhaak, Roel
Baumert, Brigitta G.
Stalpers, Lucas J. A.
Vermeulen, Louis
Watts, Colin
Bailey, David
Slotman, Ben J.
Versteeg, Rogier
Noske, David
Sminia, Peter
Tannous, Bakhos A.
Wurdinger, Tom
Koster, Jan
Westerman, Bart A.
A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities
title A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities
title_full A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities
title_fullStr A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities
title_full_unstemmed A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities
title_short A cancer drug atlas enables synergistic targeting of independent drug vulnerabilities
title_sort cancer drug atlas enables synergistic targeting of independent drug vulnerabilities
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7287046/
https://www.ncbi.nlm.nih.gov/pubmed/32523045
http://dx.doi.org/10.1038/s41467-020-16735-2
work_keys_str_mv AT narayanravis acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT molenaarpiet acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT tengjian acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT cornelissenfleurmg acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT roelofsirene acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT menezesrenee acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT dikrogier acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT lagerweijtonny acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT broersmayoran acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT petersennaomi acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT marinsotojhonalexander acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT brandseelke acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT vankuikenphilip acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT leccamariac acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT lenoskristiaanj acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT intveldsjorsgjg acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT vanwieringenwessel acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT langfrederickf acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT sulmanerik acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT verhaakroel acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT baumertbrigittag acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT stalperslucasja acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT vermeulenlouis acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT wattscolin acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT baileydavid acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT slotmanbenj acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT versteegrogier acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT noskedavid acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT sminiapeter acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT tannousbakhosa acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT wurdingertom acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT kosterjan acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT westermanbarta acancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT narayanravis cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT molenaarpiet cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT tengjian cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT cornelissenfleurmg cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT roelofsirene cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT menezesrenee cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT dikrogier cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT lagerweijtonny cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT broersmayoran cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT petersennaomi cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT marinsotojhonalexander cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT brandseelke cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT vankuikenphilip cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT leccamariac cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT lenoskristiaanj cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT intveldsjorsgjg cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT vanwieringenwessel cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT langfrederickf cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT sulmanerik cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT verhaakroel cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT baumertbrigittag cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT stalperslucasja cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT vermeulenlouis cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT wattscolin cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT baileydavid cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT slotmanbenj cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT versteegrogier cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT noskedavid cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT sminiapeter cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT tannousbakhosa cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT wurdingertom cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT kosterjan cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities
AT westermanbarta cancerdrugatlasenablessynergistictargetingofindependentdrugvulnerabilities